Biopharmaceutical company InnoCare Pharma (HKEX: 09969) (SSE: 688428), which is focused on cancer and autoimmune diseases, declared on Tuesday that the Health Sciences Authority (HSA) of Singapore has approved HIBRUKA (orelabrutinib) to treat adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
The company stated that mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin's lymphoma (NHL), which is invasive and incurable, with increasing incidence rate year by year. The disease is usually in the late stage when diagnosed and faces challenges of limited treatment and poor prognosis.
InnoCare's co-founder, chairwoman and CEO, Dr Jasmine Cui, said: "Orelabrutinib's NDA approval in Singapore marks the commercialization of InnoCare go international. As a highly selective BTK inhibitor, orelabrutinib has demonstrated good efficacy and safety in the treatment of R/R MCL. The approval in Singapore will offer a new option to the local MCL patients with the innovative therapy."
InflaRx initiates Phase III trial for vilobelimab in ulcerative pyoderma gangrenosum
3T Biosciences names new chief scientific officer
RegCell names new president, chief executive officer, and representative director
Immetas Therapeutics and GC Biopharma partner to develop mRNA therapeutics for autoimmune diseases
Hansa Biopharma announces high-level results from HNSA-5487 first-in-human trial
Bio-Thera's TOFIDENCE intravenous formulation receives US FDA for approval
MyMD Pharmaceuticals plans to showcase positive Phase 2 data for MYMD-1 at BioFuture 2023
Calliditas announces UK MHRA filing for Kinpeygo in IgA nephropathy
Kyverna Therapeutics signs license and supply agreement with Oxford Biomedica
Everest Medicines signs collaboration and license agreement with Kezar Life Sciences
Pfizer's LITFULO gains EC approval for treating severe alopecia areata in adolescents and adults
Q32 Bio doses first subject in Bempikibart proof-of-concept study
FDA grants Orphan Drug Designation to Cantargia's CAN10 for systemic sclerosis treatment